TY - GEN
T1 - Nanodroplet mediated intravascular sonothrombolysis of retracted clots
AU - Goel, Leela
AU - Wu, Huaiyu
AU - Zhang, Bohua
AU - Kim, Jinwook
AU - Dayton, Paul
AU - Xu, Zhen
AU - Jiang, Xiaoning
N1 - Publisher Copyright:
© 2020 IEEE.
PY - 2020/9/7
Y1 - 2020/9/7
N2 - Current sonothrombolysis techniques have limited efficacy for treating retracted clots. Nanodroplet (ND) mediated sonothrombolysis has the potential to facilitate tPA penetration into the dense fibrin networks of retracted clots via nanodroplet-induced cavitation. Intravascular sonothrombolysis is of interest to improve catheter directed clot treatments and mitigate off-target effects. This paper investigates the feasibility of nanodroplet-mediated sonothrombolysis with tPA to treat retracted clots, in vitro, using a forward-viewing intravascular transducer. The percent mass decrease of the retracted clots (mean ± std) were 4 ± 2%, 20 ± 3%, 23 ± 5%, 38 ± 9% for the control, tPA + US, ND + US, and ND + tPA + US groups, respectively. All of the sonothrombolysis conditions resulted in statistically significantly higher clot lysis compared to the control group (p<0.05). The combined ND + tPA + US treatment significantly outperformed the ND + US condition (p<0.05) and approached significance for the tPA + US group (p = 0.09). In summary, our forward-viewing intravascular transducer was demonstrated, for the first time, for sonothrombolysis in a retracted clot model by combining NDs and tPA.
AB - Current sonothrombolysis techniques have limited efficacy for treating retracted clots. Nanodroplet (ND) mediated sonothrombolysis has the potential to facilitate tPA penetration into the dense fibrin networks of retracted clots via nanodroplet-induced cavitation. Intravascular sonothrombolysis is of interest to improve catheter directed clot treatments and mitigate off-target effects. This paper investigates the feasibility of nanodroplet-mediated sonothrombolysis with tPA to treat retracted clots, in vitro, using a forward-viewing intravascular transducer. The percent mass decrease of the retracted clots (mean ± std) were 4 ± 2%, 20 ± 3%, 23 ± 5%, 38 ± 9% for the control, tPA + US, ND + US, and ND + tPA + US groups, respectively. All of the sonothrombolysis conditions resulted in statistically significantly higher clot lysis compared to the control group (p<0.05). The combined ND + tPA + US treatment significantly outperformed the ND + US condition (p<0.05) and approached significance for the tPA + US group (p = 0.09). In summary, our forward-viewing intravascular transducer was demonstrated, for the first time, for sonothrombolysis in a retracted clot model by combining NDs and tPA.
KW - Clot lysis
KW - Intravascular sonothrombolysis
KW - Retracted clots
KW - Sonothrombolysis
UR - http://www.scopus.com/inward/record.url?scp=85097906427&partnerID=8YFLogxK
U2 - 10.1109/IUS46767.2020.9251699
DO - 10.1109/IUS46767.2020.9251699
M3 - Conference contribution
AN - SCOPUS:85097906427
T3 - IEEE International Ultrasonics Symposium, IUS
BT - IUS 2020 - International Ultrasonics Symposium, Proceedings
PB - IEEE Computer Society
T2 - 2020 IEEE International Ultrasonics Symposium, IUS 2020
Y2 - 7 September 2020 through 11 September 2020
ER -